NYSE:NVTAInVitae Stock Price, Forecast & News

InVitae's stock was trading at $15.85 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, NVTA stock has increased by 83.0% and is now trading at $29.01.
View which stocks have been most impacted by Coronavirus.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for InVitae in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for InVitae.

InVitae is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for InVitae.

InVitae Corp (NYSE:NVTA) posted its quarterly earnings results on Tuesday, August, 4th. The medical research company reported ($0.77) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.62) by $0.15. The medical research company earned $46.20 million during the quarter, compared to analysts' expectations of $39.63 million. InVitae had a negative return on equity of 77.82% and a negative net margin of 182.73%. InVitae's revenue was down 14.4% compared to the same quarter last year. During the same period last year, the firm posted ($0.54) EPS.
View InVitae's earnings history.

6 equities research analysts have issued 1 year price targets for InVitae's shares. Their forecasts range from $20.00 to $37.25. On average, they expect InVitae's share price to reach $32.54 in the next twelve months. This suggests a possible upside of 12.2% from the stock's current price.
View analysts' price targets for InVitae.

Press coverage about NVTA stock has trended negative on Tuesday, InfoTrie reports. InfoTrie identifies negative and positive press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. InVitae earned a news sentiment score of -2.1 on InfoTrie's scale. They also gave news articles about the medical research company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock's share price in the next several days.
View the latest news about InVitae.

Some companies that are related to InVitae include Guardant Health (GH), ELEKTA AB/ADR (EKTAY), Natera (NTRA), Veracyte (VCYT), CareDx (CDNA), RadNet (RDNT), Fulgent Genetics (FLGT), Castle Biosciences (CSTL), Personalis (PSNL), ALX Oncology (RNLX), Progenity (PROG), Centogene (CNTG), DermTech (DMTK), Biocept (BIOC) and Enzo Biochem (ENZ).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other InVitae investors own include NVIDIA (NVDA), Square (SQ), Roku (ROKU), Shopify (SHOP), Trade Desk (TTD), Alibaba Group (BABA), salesforce.com (CRM), Walt Disney (DIS), Okta (OKTA) and Twilio (TWLO).

(NVTA) raised $76 million in an initial public offering (IPO) on Thursday, February 12th 2015. The company issued 5,400,000 shares at $13.00-$15.00 per share. J.P. Morgan served as the underwriter for the IPO and Cowen and Company and Leerink Partners were co-managers.

InVitae trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVTA."

InVitae's stock is owned by a number of retail and institutional investors. Top institutional investors include Sumitomo Mitsui Trust Holdings Inc. (9.79%), Macquarie Group Ltd. (3.01%), Victory Capital Management Inc. (0.83%), Jennison Associates LLC (0.31%), HighTower Advisors LLC (0.23%) and Swiss National Bank (0.21%). Company insiders that own InVitae stock include E Lee Bendekgey, Eric Aguiar, Geoffrey Crouse, Katherine Stueland, Patty Dumond, Randal W Scott, Robert L Nussbaum, Sean E George, Shelly D Guyer and Thomas Brida.
View institutional ownership trends for InVitae.

NVTA stock was sold by a variety of institutional investors in the last quarter, including Sumitomo Mitsui Trust Holdings Inc., Russell Investments Group Ltd., Principal Financial Group Inc., PNC Financial Services Group Inc., Profit Investment Management LLC, CAPROCK Group Inc., OTA Financial Group L.P., and Dupont Capital Management Corp. Company insiders that have sold InVitae company stock in the last year include E Lee Bendekgey, Eric Aguiar, Geoffrey Crouse, Katherine Stueland, Randal W Scott, Robert L Nussbaum, Sean E George, Shelly D Guyer, and Thomas Brida.
View insider buying and selling activity for InVitae.

NVTA stock was purchased by a variety of institutional investors in the last quarter, including Macquarie Group Ltd., Victory Capital Management Inc., Fagan Associates Inc., Mackay Shields LLC, Mutual of America Capital Management LLC, Swiss National Bank, AE Wealth Management LLC, and Sawtooth Solutions LLC.
View insider buying and selling activity for InVitae.

Shares of NVTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of NVTA stock can currently be purchased for approximately $29.01.

InVitae has a market capitalization of $3.82 billion and generates $216.82 million in revenue each year. The medical research company earns $-241,960,000.00 in net income (profit) each year or ($2.28) on an earnings per share basis. InVitae employs 1,300 workers across the globe.

The official website for InVitae is www.invitae.com.

InVitae's mailing address is 1400 16th Street, SAN FRANCISCO CA, 94103. The medical research company can be reached via phone at 415-374-7782 or via email at [email protected]